Gregory J. Kato

List of Publications by Citations

Source: https://exaly.com/author-pdf/9319409/gregory-j-kato-publications-by-citations.pdf
Version: 2024-04-19

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

308 papers	11,688 citations	60 h-index	102 g-index
337 ext. papers	13,227 ext. citations	5.6 avg, IF	6.19 L-index

#	Paper	IF	Citations
308	Deconstructing sickle cell disease: reappraisal of the role of hemolysis in the development of clinical subphenotypes. *Blood Reviews*, **2007**, 21, 37-47	11.1	634
307	Dysregulated arginine metabolism, hemolysis-associated pulmonary hypertension, and mortality in sickle cell disease. *JAMA - Journal of the American Medical Association*, **2005**, 294, 81-90	27.4	522
306	Lactate dehydrogenase as a biomarker of hemolysis-associated nitric oxide resistance, priapism, leg ulceration, pulmonary hypertension, and death in patients with sickle cell disease. *Blood*, **2006**, 107, 2279-85	2.3	489
305	An amino-terminal c-myc domain required for neoplastic transformation activates transcription. *Molecular and Cellular Biology*, **1990**, 10, 5914-20	4.8	389
304	Sickle cell disease. *Nature Reviews Disease Primers*, **2018**, 4, 18010	51.1	373
303	Intravascular hemolysis and the pathophysiology of sickle cell disease. *Journal of Clinical Investigation*, **2017**, 127, 750-760	15.9	301
302	Platelet activation in patients with sickle disease, hemolysis-associated pulmonary hypertension, and nitric oxide scavenging by cell-free hemoglobin. *Blood*, **2007**, 110, 2166-72	2.2	269
301	Max: functional domains and interaction with c-Myc. *Genes and Development*, **1992**, 6, 81-92	12.6	233
300	Diastolic dysfunction is an independent risk factor for death in patients with sickle cell disease. *Journal of the American College of Cardiology*, **2007**, 49, 472-9	15.1	219
299	Hospitalization for pain in patients with sickle cell disease treated with sildenafil for elevated TRV and low exercise capacity. *Blood*, **2011**, 118, 855-64	2.2	179
298	Sildenafil therapy in patients with sickle cell disease and pulmonary hypertension. *British Journal of Haematology*, **2005**, 130, 445-53	4.5	170
297	Levels of soluble endothelium-derived adhesion molecules in patients with sickle cell disease are associated with pulmonary hypertension, organ dysfunction, and mortality. *British Journal of Haematology*, **2005**, 130, 943-53	4.5	163
296	Discrimination between related DNA sites by a single amino acid residue of Myc-related basic-helix-loop-helix proteins. *Proceedings of the National Academy of Sciences of the United States of America*, **1992**, 89, 599-602	11.5	158
295	Intracellular leucine zipper interactions suggest c-Myc hetero-oligomerization. *Molecular and Cellular Biology*, **1991**, 11, 954-62	4.8	156
294	An official American Thoracic Society clinical practice guideline: diagnosis, risk stratification, and management of pulmonary hypertension of sickle cell disease. *American Journal of Respiratory and Critical Care Medicine*, **2014**, 189, 727-40	10.2	154
293	Mortality in adults with sickle cell disease and pulmonary hypertension. *JAMA - Journal of the American Medical Association*, **2012**, 307, 1254-6	27.4	152
292	Nitric oxide for inhalation in the acute treatment of sickle cell pain crisis: a randomized controlled trial. *JAMA - Journal of the American Medical Association*, **2011**, 305, 893-902	27.4	151

291	N-terminal pro-brain natriuretic peptide levels and risk of death in sickle cell disease. *JAMA - Journal of the American Medical Association*, **2006**, 296, 310-8	27.4	143
290	Elevated tricuspid regurgitant jet velocity in children and adolescents with sickle cell disease: association with hemolysis and hemoglobin oxygen desaturation. *Haematologica*, **2009**, 94, 340-7	6.6	142
289	Function of the c-Myc oncoprotein. *FASEB Journal*, **1992**, 6, 3065-72	0.9	142
288	The relationship between the severity of hemolysis, clinical manifestations and risk of death in 415 patients with sickle cell anemia in the US and Europe. *Haematologica*, **2013**, 98, 464-72	6.6	135
287	A network model to predict the risk of death in sickle cell disease. *Blood*, **2007**, 110, 2727-35	2.2	132
286	Chronic hyper-hemolysis in sickle cell anemia: association of vascular complications and mortality with less frequent vasoocclusive pain. *PLoS ONE*, **2008**, 3, e2095	3.7	123
285	Mechanisms of hemolysis-associated platelet activation. *Journal of Thrombosis and Haemostasis*, **2013**, 11, 2148-54	15.4	111
284	Amplified expression profiling of platelet transcriptome reveals changes in arginine metabolic pathways in patients with sickle cell disease. *Circulation*, **2007**, 115, 1551-62	16.7	107
283	Pulmonary complications of sickle cell disease. *American Journal of Respiratory and Critical Care Medicine*, **2012**, 185, 1154-65	10.2	106
282	Sickle cell disease and nitric oxide: a paradigm shift?. *International Journal of Biochemistry and Cell Biology*, **2006**, 38, 1237-43	5.6	103
281	Hemodynamic predictors of mortality in adults with sickle cell disease. *American Journal of Respiratory and Critical Care Medicine*, **2013**, 187, 840-7	10.2	98
280	Echocardiographic markers of elevated pulmonary pressure and left ventricular diastolic dysfunction are associated with exercise intolerance in adults and adolescents with homozygous sickle cell anemia in the United States and United Kingdom. *Circulation*, **2011**, 124, 1452-60	16.7	97
279	Elevated sphingosine-1-phosphate promotes sickling and sickle cell disease progression. *Journal of Clinical Investigation*, **2014**, 124, 2750-61	15.9	93
278	Relative systemic hypertension in patients with sickle cell disease is associated with risk of pulmonary hypertension and renal insufficiency. *American Journal of Hematology*, **2008**, 83, 15-8	7.1	90
277	Hemolysis-associated pulmonary hypertension in thalassemia. *Annals of the New York Academy of Sciences*, **2005**, 1054, 481-5	6.5	90
276	Severity of pulmonary hypertension during vaso-occlusive pain crisis and exercise in patients with sickle cell disease. *British Journal of Haematology*, **2007**, 136, 319-25	4.5	89
275	Circulating blood endothelial nitric oxide synthase contributes to the regulation of systemic blood pressure and nitrite homeostasis. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2013**, 33, 1861-71	9.4	85
274	Nitric oxide and arginine dysregulation: a novel pathway to pulmonary hypertension in hemolytic disorders. *Current Molecular Medicine*, **2008**, 8, 620-32	2.5	84

273	Risk factors for death in 632 patients with sickle cell disease in the United States and United Kingdom. *PLoS ONE*, **2014**, 9, e99489	3.7	82
272	Pulmonary hypertension in children and adolescents with sickle cell disease. *Pediatric Cardiology*, **2008**, 29, 309-12	2.1	80
271	Endogenous nitric oxide synthase inhibitors in sickle cell disease: abnormal levels and correlations with pulmonary hypertension, desaturation, haemolysis, organ dysfunction and death. *British Journal of Haematology*, **2009**, 145, 506-13	4.5	79
270	Cardiopulmonary complications of sickle cell disease: role of nitric oxide and hemolytic anemia. *Hematology American Society of Hematology Education Program*, **2005**, 2005, 51-7	3.1	79
269	RV dysfunction by MRI is associated with elevated transpulmonary gradient and poor prognosis in patients with sickle cell associated pulmonary hypertension. *Journal of Cardiovascular Magnetic Resonance*, **2013**, 15,	6.9	78
268	Pulmonary hypertension in sickle cell disease: relevance to children. *Pediatric Hematology and Oncology*, **2007**, 24, 159-70	1.7	78
267	Cerebrovascular disease associated with sickle cell pulmonary hypertension. *American Journal of Hematology*, **2006**, 81, 503-10	7.1	76
266	Severe painful vaso-occlusive crises and mortality in a contemporary adult sickle cell anemia cohort study. *PLoS ONE*, **2013**, 8, e79923	3.7	76
265	Corticosteroids and increased risk of readmission after acute chest syndrome in children with sickle cell disease. *Pediatric Blood and Cancer*, **2008**, 50, 1006-12	3	75
264	Lung vaso-occlusion in sickle cell disease mediated by arteriolar neutrophil-platelet microemboli. *JCI Insight*, **2017**, 2, e89761	9.9	74
263	Markers of severe vaso-occlusive painful episode frequency in children and adolescents with sickle cell anemia. *Journal of Pediatrics*, **2012**, 160, 286-90	3.6	73
262	Prevalence and risk factors for pulmonary artery systolic hypertension among sickle cell disease patients in Nigeria. *American Journal of Hematology*, **2008**, 83, 485-90	7.1	73
261	High levels of placenta growth factor in sickle cell disease promote pulmonary hypertension. *Blood*, **2010**, 116, 109-12	2.2	72
260	Inhibition of PDE4 phosphodiesterase activity induces growth suppression, apoptosis, glucocorticoid sensitivity, p53, and p21(WAF1/CIP1) proteins in human acute lymphoblastic leukemia cells. *Blood*, **2002**, 99, 3390-7	2.2	72
259	Activation domains of L-Myc and c-Myc determine their transforming potencies in rat embryo cells. *Molecular and Cellular Biology*, **1992**, 12, 3130-7	4.8	72
258	Kinetics of sickle cell biorheology and implications for painful vasoocclusive crisis. *Proceedings of the National Academy of Sciences of the United States of America*, **2015**, 112, 1422-7	11.5	70
257	Sickle cell disease and pulmonary hypertension in Africa: a global perspective and review of epidemiology, pathophysiology, and management. *American Journal of Hematology*, **2008**, 83, 63-70	7.1	70
256	Evolution of novel small-molecule therapeutics targeting sickle cell vasculopathy. *JAMA - Journal of the American Medical Association*, **2008**, 300, 2638-46	27.4	66

255	A systematic comparison and evaluation of high density exon arrays and RNA-seq technology used to unravel the peripheral blood transcriptome of sickle cell disease. *BMC Medical Genomics*, **2012**, 5, 28	3.7	65
254	Proteomic identification of altered apolipoprotein patterns in pulmonary hypertension and vasculopathy of sickle cell disease. *Blood*, **2009**, 113, 1122-8	2.2	65
253	Meta-analysis of 2040 sickle cell anemia patients: BCL11A and HBS1L-MYB are the major modifiers of HbF in African Americans. *Blood*, **2012**, 120, 1961-2	2.2	64
252	Plasma thrombospondin-1 is increased during acute sickle cell vaso-occlusive events and associated with acute chest syndrome, hydroxyurea therapy, and lower hemolytic rates. *American Journal of Hematology*, **2012**, 87, 326-30	7.1	60
251	Elevated tricuspid regurgitation velocity and decline in exercise capacity over 22 months of follow up in children and adolescents with sickle cell anemia. *Haematologica*, **2011**, 96, 33-40	6.6	60
250	Endothelin receptor antagonists for pulmonary hypertension in adult patients with sickle cell disease. *British Journal of Haematology*, **2009**, 147, 737-43	4.5	60
249	Pleiotropic effects of intravascular haemolysis on vascular homeostasis. *British Journal of Haematology*, **2010**, 148, 690-701	4.5	57
248	E2A basic-helix-loop-helix transcription factors are negatively regulated by serum growth factors and by the Id3 protein. *Nucleic Acids Research*, **1996**, 24, 2813-20	20.1	57
247	Framing the research agenda for sickle cell trait: building on the current understanding of clinical events and their potential implications. *American Journal of Hematology*, **2012**, 87, 340-6	7.1	56
246	Lipid levels in sickle-cell disease associated with haemolytic severity, vascular dysfunction and pulmonary hypertension. *British Journal of Haematology*, **2010**, 149, 436-45	4.5	56
245	Angiogenic and inflammatory markers of cardiopulmonary changes in children and adolescents with sickle cell disease. *PLoS ONE*, **2009**, 4, e7956	3.7	56
244	Relationship of erythropoietin, fetal hemoglobin, and hydroxyurea treatment to tricuspid regurgitation velocity in children with sickle cell disease. *Blood*, **2009**, 114, 4639-44	2.2	56
243	Sodium nitrite promotes regional blood flow in patients with sickle cell disease: a phase I/II study. *British Journal of Haematology*, **2008**, 142, 971-8	4.5	56
242	Sleep disturbance, depression and pain in adults with sickle cell disease. *BMC Psychiatry*, **2014**, 14, 207	4.2	55
241	Prospective evaluation of haemoglobin oxygen saturation at rest and after exercise in paediatric sickle cell disease patients. *British Journal of Haematology*, **2009**, 147, 352-9	4.5	53
240	Hematologic, biochemical, and cardiopulmonary effects of L-arginine supplementation or phosphodiesterase 5 inhibition in patients with sickle cell disease who are on hydroxyurea therapy. *European Journal of Haematology*, **2009**, 82, 315-21	3.8	52
239	Pulmonary hypertension and NO in sickle cell. *Blood*, **2010**, 116, 852-4	2.2	51
238	Vasculopathy, inflammation, and blood flow in leg ulcers of patients with sickle cell anemia. *American Journal of Hematology*, **2014**, 89, 1-6	7.1	49

237	Prospective echocardiography assessment of pulmonary hypertension and its potential etiologies in children with sickle cell disease. *American Journal of Cardiology*, **2009**, 104, 713-20	3	49
236	Mutations and polymorphisms in hemoglobin genes and the risk of pulmonary hypertension and death in sickle cell disease. *American Journal of Hematology*, **2008**, 83, 6-14	7.1	49
235	Iron, inflammation, and early death in adults with sickle cell disease. *Circulation Research*, **2015**, 116, 298-306	13.7	48
234	Diastolic dysfunction in sickle cell. *Blood*, **2010**, 116, 1-2	2.2	47
233	Imaging flow cytometry for automated detection of hypoxia-induced erythrocyte shape change in sickle cell disease. *American Journal of Hematology*, **2014**, 89, 598-603	7.1	46
232	Therapeutic strategies to alter the oxygen affinity of sickle hemoglobin. *Hematology/Oncology Clinics of North America*, **2014**, 28, 217-31	3.1	45
231	Leg ulcers in sickle cell disease: current patterns and practices. *Hemoglobin*, **2013**, 37, 325-32	0.6	44
230	Clinical Outcomes Associated With Sickle Cell Trait: A Systematic Review. *Annals of Internal Medicine*, **2018**, 169, 619-627	8	44
229	New developments in anti-sickling agents: can drugs directly prevent the polymerization of sickle haemoglobin in vivo?. *British Journal of Haematology*, **2016**, 175, 24-30	4.5	43
228	Fetal haemoglobin response to hydroxycarbamide treatment and sar1a promoter polymorphisms in sickle cell anaemia. *British Journal of Haematology*, **2008**, 141, 254-9	4.5	42
227	Critical Reviews: How we treat sickle cell patients with leg ulcers. *American Journal of Hematology*, **2016**, 91, 22-30	7.1	40
226	Diet-induced weight loss in overweight or obese women and changes in high-density lipoprotein levels and function. *Obesity*, **2012**, 20, 2057-62	8	40
225	NT-pro brain natriuretic peptide levels and the risk of death in the cooperative study of sickle cell disease. *British Journal of Haematology*, **2011**, 154, 512-20	4.5	40
224	Increased pulmonary pressures and myocardial wall stress in children with severe malaria. *Journal of Infectious Diseases*, **2010**, 202, 791-800	7	40
223	Haptoglobin halts hemoglobin havoc. *Journal of Clinical Investigation*, **2009**, 119, 2140-2	15.9	39
222	Hydroxyurea-induced expression of glutathione peroxidase 1 in red blood cells of individuals with sickle cell anemia. *Antioxidants and Redox Signaling*, **2010**, 13, 1-11	8.4	38
221	Extensive ex vivo expansion of functional human erythroid precursors established from umbilical cord blood cells by defined factors. *Molecular Therapy*, **2014**, 22, 451-463	11.7	37
220	Heme-bound iron activates placenta growth factor in erythroid cells via erythroid Krppel-like factor. *Blood*, **2014**, 124, 946-54	2.2	37

219	Combination erythropoietin-hydroxyurea therapy in sickle cell disease: experience from the National Institutes of Health and a literature review. *Haematologica*, **2006**, 91, 1076-83	6.6	36
218	Abnormal pulmonary function and associated risk factors in children and adolescents with sickle cell anemia. *Journal of Pediatric Hematology/Oncology*, **2014**, 36, 185-9	1.2	35
217	Genetic determinants of haemolysis in sickle cell anaemia. *British Journal of Haematology*, **2013**, 161, 270-8	4.5	35
216	Hemolysis-associated hypercoagulability in sickle cell disease: the plot (and blood) thickens!. *Haematologica*, **2008**, 93, 1-3	6.6	35
215	Laboratory and echocardiography markers in sickle cell patients with leg ulcers. *American Journal of Hematology*, **2011**, 86, 705-8	7.1	34
214	High glucocorticoid receptor content of leukemic blasts is a favorable prognostic factor in childhood acute lymphoblastic leukemia. *Blood*, **1993**, 82, 2304-2309	2.2	34
213	Liver injury is associated with mortality in sickle cell disease. *Alimentary Pharmacology and Therapeutics*, **2015**, 42, 912-21	6.1	33
212	A novel molecular signature for elevated tricuspid regurgitation velocity in sickle cell disease. *American Journal of Respiratory and Critical Care Medicine*, **2012**, 186, 359-68	10.2	33
211	Platelet Extracellular Vesicles Drive Inflammasome-IL-1-Dependent Lung Injury in Sickle Cell Disease. *American Journal of Respiratory and Critical Care Medicine*, **2020**, 201, 33-46	10.2	33
210	Topical sodium nitrite for chronic leg ulcers in patients with sickle cell anaemia: a phase 1 dose-finding safety and tolerability trial. *Lancet Haematology,the*, **2014**, 1, e95-e103	14.6	32
209	A GCH1 haplotype confers sex-specific susceptibility to pain crises and altered endothelial function in adults with sickle cell anemia. *American Journal of Hematology*, **2014**, 89, 187-93	7.1	31
208	Simultaneous polymerization and adhesion under hypoxia in sickle cell disease. *Proceedings of the National Academy of Sciences of the United States of America*, **2018**, 115, 9473-9478	11.5	31
207	Priapism in sickle-cell disease: a hematologist perspective. *Journal of Sexual Medicine*, **2012**, 9, 70-8	1.1	30
206	Human genetic diseases of proteolysis. *Human Mutation*, **1999**, 13, 87-98	4.7	30
205	Cellular normoxic biophysical markers of hydroxyurea treatment in sickle cell disease. *Proceedings of the National Academy of Sciences of the United States of America*, **2016**, 113, 9527-32	11.5	30
204	Improvement in hemolysis and pulmonary arterial systolic pressure in adult patients with sickle cell disease during treatment with hydroxyurea. *American Journal of Hematology*, **2009**, 84, 530-32	7.1	28
203	Clinical correlates of acute pulmonary events in children and adolescents with sickle cell disease. *European Journal of Haematology*, **2013**, 91, 62-8	3.8	27
202	Prominent role of platelets in the formation of circulating neutrophil-red cell heterocellular aggregates in sickle cell anemia. *Haematologica*, **2014**, 99, e214-7	6.6	26

201	Imaging flow cytometry for morphologic and phenotypic characterization of rare circulating endothelial cells. *Cytometry Part B - Clinical Cytometry*, **2013**, 84, 379-89	3.4	26
200	Association of G6PD with lower haemoglobin concentration but not increased haemolysis in patients with sickle cell anaemia. *British Journal of Haematology*, **2010**, 150, 218-25	4.5	25
199	Segmentation and quantification of pulmonary artery for noninvasive CT assessment of sickle cell secondary pulmonary hypertension. *Medical Physics*, **2010**, 37, 1522-32	4.4	25
198	Identification and characterization of the novel centrosome-associated protein CCCAP. *Gene*, **2003**, 303, 35-46	3.8	25
197	New insights into sickle cell disease: mechanisms and investigational therapies. *Current Opinion in Hematology*, **2016**, 23, 224-32	3.3	24
196	A retrospective review of acupuncture use for the treatment of pain in sickle cell disease patients: descriptive analysis from a single institution. *Clinical Journal of Pain*, **2014**, 30, 825-30	3.5	23
195	Ancestry of African Americans with sickle cell disease. *Blood Cells, Molecules, and Diseases*, **2011**, 47, 41-5	2.1	23
194	Near-infrared spectra absorbance of blood from sickle cell patients and normal individuals. *Hematology*, **2009**, 14, 46-8	2.2	23
193	Successful treatment of life-threatening acute chest syndrome of sickle cell disease with venovenous extracorporeal membrane oxygenation. *Journal of Pediatric Hematology/Oncology*, **1997**, 19, 459-61	1.2	23
192	Elevated pulse pressure is associated with hemolysis, proteinuria and chronic kidney disease in sickle cell disease. *PLoS ONE*, **2014**, 9, e114309	3.7	22
191	Homozygous factor-V mutation as a genetic cause of perinatal thrombosis and cerebral palsy. *Developmental Medicine and Child Neurology*, **1999**, 41, 777-80	3.3	22
190	Thrombospondin-1 inhibits ADAMTS13 activity in sickle cell disease. *Haematologica*, **2013**, 98, e132-4	6.6	21
189	Expression of regulatory platelet microRNAs in patients with sickle cell disease. *PLoS ONE*, **2013**, 8, e60932	3.7	19
188	Pulmonary artery pressure and iron deficiency in patients with upregulation of hypoxia sensing due to homozygous VHL(R200W) mutation (Chuvash polycythemia). *Haematologica*, **2012**, 97, 193-200	6.6	19
187	High-density lipoprotein cholesterol efflux, nitration of apolipoprotein A-I, and endothelial function in obese women. *American Journal of Cardiology*, **2012**, 109, 527-32	3	18
186	Reduced sensitivity of the ferroportin Q248H mutant to physiological concentrations of hepcidin. *Haematologica*, **2013**, 98, 455-63	6.6	18
185	The proteome of sickle cell disease: insights from exploratory proteomic profiling. *Expert Review of Proteomics*, **2010**, 7, 833-48	4.2	18
184	Apolipoprotein A-I and serum amyloid A plasma levels are biomarkers of acute painful episodes in patients with sickle cell disease. *Haematologica*, **2010**, 95, 1467-72	6.6	18

183	Novel small molecule therapeutics for sickle cell disease: nitric oxide, carbon monoxide, nitrite, and apolipoprotein A-I. *Hematology American Society of Hematology Education Program*, **2008**, 186-92	3.1	18
182	Atorvastatin reduces serum cholesterol and triglycerides with limited improvement in vascular function in adults with sickle cell anemia. *Haematologica*, **2012**, 97, 1768-70	6.6	17
181	The mUBC9 murine ubiquitin conjugating enzyme interacts with the E2A transcription factors. *Gene* , **1997**, 201, 169-77	3.8	17
180	Infrared imaging of nitric oxide-mediated blood flow in human sickle cell disease. *Microvascular Research*, **2012**, 84, 262-9	3.7	16
179	Identifying Clinical and Research Priorities in Sickle Cell Lung Disease. An Official American Thoracic Society Workshop Report. *Annals of the American Thoracic Society*, **2019**, 16, e17-e32	4.7	15
178	Strategic plan for pediatric respiratory diseases research: an NHLBI working group report. *Proceedings of the American Thoracic Society*, **2009**, 6, 1-10		15
177	Phase 1 Clinical Trial Of The Candidate Anti-Sickling Agent Aes-103 In Adults With Sickle Cell Anemia. *Blood*, **2013**, 122, 1009-1009	2.2	15
176	The Worst Things in Life are Free: The Role of Free Heme in Sickle Cell Disease. *Frontiers in Immunology*, **2020**, 11, 561917	8.4	15
175	A fluorescence method to detect and quantitate sterol esterification by lecithin:cholesterol acyltransferase. *Analytical Biochemistry*, **2013**, 441, 80-6	3.1	13
174	Lactate dehydrogenase and hemolysis in sickle cell disease. *Blood*, **2013**, 122, 1091-2	2.2	13
173	Reconstruction of Thermographic Signals to Map Perforator Vessels in Humans. *Quantitative InfraRed Thermography Journal*, **2012**, 9, 123-133	1.1	13
172	Hydroxyurea Utilization in Nigeria, a Lesson in Public Health.. *Blood*, **2007**, 110, 80-80	2.2	13
171	Prostacyclin-analog therapy in sickle cell pulmonary hypertension. *Haematologica*, **2017**, 102, e163-e165	6.6	12
170	Predictors of osteoclast activity in patients with sickle cell disease. *Haematologica*, **2011**, 96, 1092-8	6.6	12
169	Liver stiffness increases acutely during sickle cell vaso-occlusive crisis. *American Journal of Hematology*, **2013**, 88, E250-4	7.1	11
168	Effects of a single sickling event on the mechanical fragility of sickle cell trait erythrocytes. *Hemoglobin*, **2010**, 34, 24-36	0.6	11
167	Strategic plan for pediatric respiratory diseases research: an NHLBI working group report. *Pediatric Pulmonology*, **2009**, 44, 2-13	3.5	11
166	Safety and Efficacy of Sildenafil Therapy for Doppler-Defined Pulmonary Hypertension in Patients with Sickle Cell Disease: Preliminary Results of the Walk-PHaSST Clinical Trial.. *Blood*, **2009**, 114, 571-571	2.2	11

165	A Phase 1, First-in-Man, Dose-Response Study of Aes-103 (5-HMF), an Anti-Sickling, Allosteric Modifier of Hemoglobin Oxygen Affinity in Healthy Norman Volunteers. *Blood*, **2012**, 120, 3210-3210	2.2	11
164	End points for sickle cell disease clinical trials: renal and cardiopulmonary, cure, and low-resource settings. *Blood Advances*, **2019**, 3, 4002-4020	7.8	11
163	Defective nitric oxide metabolism in sickle cell disease. *Pediatric Blood and Cancer*, **2015**, 62, 373-4	3	10
162	Microvascular oxygen consumption during sickle cell pain crisis. *Blood*, **2014**, 123, 3101-4	2.2	10
161	Pulmonary Hypertension in Sickle Cell Disease: Cardiopulmonary Evaluation and Response to Chronic Phosphodiesterase 5 Inhibitor Therapy.. *Blood*, **2004**, 104, 235-235	2.2	10
160	Effect of extended-release niacin on serum lipids and on endothelial function in adults with sickle cell anemia and low high-density lipoprotein cholesterol levels. *American Journal of Cardiology*, **2013**, 112, 1499-504	3	9
159	Skeletal and myocardial microvascular blood flow in hydroxycarbamide-treated patients with sickle cell disease. *British Journal of Haematology*, **2017**, 179, 648-656	4.5	9
158	Vascular complications after splenectomy for hematologic disorders. *Blood*, **2009**, 114, 5404	2.2	9
157	Effect of Poloxamer 188 vs Placebo on Painful Vaso-Occlusive Episodes in Children and Adults With Sickle Cell Disease: A Randomized Clinical Trial. *JAMA - Journal of the American Medical Association*, **2021**, 325, 1513-1523	27.4	9
156	Elevated transpulmonary gradient and cardiac magnetic resonance-derived right ventricular remodeling predict poor outcomes in sickle cell disease. *Haematologica*, **2016**, 101, e40-3	6.6	8
155	No NO means yes to sickle red cell adhesion. *Blood*, **2014**, 123, 1780-2	2.2	8
154	Abstract Animations for the Communication and Assessment of Pain in Adults: Cross-Sectional Feasibility Study. *Journal of Medical Internet Research*, **2018**, 20, e10056	7.6	8
153	Free heme regulates placenta growth factor through NRF2-antioxidant response signaling. *Free Radical Biology and Medicine*, **2019**, 143, 300-308	7.8	7
152	Tricuspid regurgitation velocity and other biomarkers of mortality in children, adolescents and young adults with sickle cell disease in the United States: The PUSH study. *American Journal of Hematology*, **2020**, 95, 766-774	7.1	7
151	Computed tomography correlates with cardiopulmonary hemodynamics in pulmonary hypertension in adults with sickle cell disease. *Pulmonary Circulation*, **2014**, 4, 319-29	2.7	7
150	NT-proBNP as a marker of cardiopulmonary status in sickle cell anaemia in Africa. *British Journal of Haematology*, **2010**, 150, 102-7	4.5	7
149	The CYB5R3 and G6PD A alleles modify severity of anemia in malaria and sickle cell disease. *American Journal of Hematology*, **2020**, 95, 1269-1279	7.1	7
148	DNA binding by the Myc oncoproteins. *Cancer Treatment and Research*, **1992**, 63, 313-25	3.5	7

147	Haem augments and iron chelation decreases toll-like receptor 4 mediated inflammation in monocytes from sickle cell patients. *British Journal of Haematology*, **2018**, 181, 552-554	4.5	6
146	Imaging flow cytometry documents incomplete resistance of human sickle F-cells to ex vivo hypoxia-induced sickling. *Blood*, **2014**, 124, 658-60	2.2	6
145	Anti-haemolytic effect of senicapoc and decrease in NT-proBNP in adults with sickle cell anaemia. *British Journal of Haematology*, **2011**, 155, 634-6	4.5	6
144	Heme Induces IL-6 and Cardiac Hypertrophy Genes Transcripts in Sickle Cell Mice. *Frontiers in Immunology*, **2020**, 11, 1910	8.4	6
143	Thrombospondin-1 gene polymorphism is associated with estimated pulmonary artery pressure in patients with sickle cell anemia. *American Journal of Hematology*, **2017**, 92, E31-E34	7.1	5
142	Rapid vs. delayed infrared responses after ischemia reveal recruitment of different vascular beds. *Quantitative InfraRed Thermography Journal*, **2015**, 12, 173-183	1.1	5
141	Iron restriction in sickle cell anemia: Time for controlled clinical studies. *American Journal of Hematology*, **2015**, 90, E217	7.1	5
140	Infusion of hemolyzed red blood cells within peripheral blood stem cell grafts in patients with and without sickle cell disease. *Blood*, **2012**, 119, 5671-3	2.2	5
139	Mechanisms and Clinical Complications of Hemolysis in Sickle Cell Disease and Thalassemia201-224		5
138	Thrombin Generation in Sickle Cell Disease: Insights From Computerized Automated Thrombography.. *Blood*, **2009**, 114, 2587-2587	2.2	5
137	Iron deficiency decreases hemolysis in sickle cell anemia. *Revista Brasileira De Hematologia E Hemoterapia*, **2009**, 31, 51-53		5
136	Sickle Cell Imaging Flow Cytometry Assay (SIFCA). *Methods in Molecular Biology*, **2016**, 1389, 279-92	1.4	5
135	Oscillatory haematopoiesis in adults with sickle cell disease treated with hydroxycarbamide. *British Journal of Haematology*, **2015**, 168, 737-46	4.5	4
134	Severe pulmonary hypertension in an adolescent with sickle cell disease. *American Journal of Hematology*, **2008**, 83, 71-2	7.1	4
133	Childhood Hodgkin and non-Hodgkin lymphomas. *Pediatrics in Review*, **1990**, 12, 171-9	1.1	4
132	NT-Pro Brain Natriuretic Peptide Levels and the Risk of Stroke and Death in the Cooperative Study of Sickle Cell Disease.. *Blood*, **2009**, 114, 1541-1541	2.2	4
131	A GCH1 Haplotype Associated with Susceptibility to Vasoocclusive Pain and Impaired Vascular Function in Sickle Cell Anemia.. *Blood*, **2009**, 114, 575-575	2.2	4
130	Inflammation and Sickle Cell Anemia **2016**, 177-211		4

129	Nrf2 deficiency in mice attenuates erythropoietic stress-related macrophage hypercellularity. *Experimental Hematology*, **2020**, 84, 19-28.e4	3.1	4
128	Sickle cells and sickle trait in thrombosis. *Blood*, **2019**, 133, 2463	2.2	3
127	Gout and sickle cell disease: not all pain is sickle cell pain. *British Journal of Haematology*, **2015**, 171, 872-5	4.5	3
126	Impaired Bile Secretion Promotes Hepatobiliary Injury in Sickle Cell Disease. *Hepatology*, **2020**, 72, 2165-2181	11.1	3
125	Sickle cell vasculopathy: vascular phenotype on fire!. *Journal of Physiology*, **2019**, 597, 993-994	3.9	3
124	Cardiac expression of HMOX1 and PGF in sickle cell mice and haem-treated wild type mice dominates organ expression profiles via Nrf2 (Nfe2l2). *British Journal of Haematology*, **2019**, 187, 666-675	4.5	3
123	Plasma-Derived Hemopexin as a Candidate Therapeutic Agent for Acute Vaso-Occlusion in Sickle Cell Disease: Preclinical Evidence.. *Journal of Clinical Medicine*, **2022**, 11,	5.1	3
122	The Hyperhemolysis Phenotype in Sickle Cell Anemia: Increased Risk of Leg Ulcers, Priapism, Pulmonary Hypertension and Death with Decreased Risk of Vasoocclusive Events.. *Blood*, **2006**, 108, 787-787	2.2	3
121	Risk Factors for Echocardiography-Determined Cardiopulmonary Abnormalities In Sickle Cell Anemia In the Walk-PHaSST Study. *Blood*, **2010**, 116, 260-260	2.2	3
120	Hemodynamic Parameters Predict Mortality In Sickle Cell Disease-Related Pulmonary Hypertension. *Blood*, **2010**, 116, 2668-2668	2.2	3
119	Sleep phenotype in the Townes mouse model of sickle cell disease. *Sleep and Breathing*, **2019**, 23, 333-339	3.1	3
118	Brief topical sodium nitrite and its impact on the quality of life in patients with sickle leg ulcers. *Medicine (United States)*, **2018**, 97, e12614	1.8	3
117	Validation of a composite vascular high-risk profile for adult patients with sickle cell disease. *American Journal of Hematology*, **2019**, 94, E312-E314	7.1	2
116	Management of patients with sickle cell disease. *JAMA - Journal of the American Medical Association* , **2015**, 313, 91	27.4	2
115	Circulating endothelial progenitor cells in adults with sickle cell disease. *Pulmonary Circulation*, **2013**, 3, 448-9	2.7	2
114	Evaluation Of Sildenafil Therapy For Patients With Sickle Cell Disease And Increased Tricuspid Regurgitant Velocity: Preliminary Results Of The Walk-PHaSST Trial **2010**,		2
113	Pulmonary complications of sickle cell disease. *New England Journal of Medicine*, **2009**, 360, 1044; author reply 1044-5	59.2	2
112	Characterizing non-linear dependencies among pairs of clinical variables and imaging data. *Annual International Conference of the IEEE Engineering in Medicine and Biology Society IEEE Engineering in Medicine and Biology Society Annual International Conference*, **2012**, 2012, 2700-3	0.9	2

111	Homozygous factor-V mutation as a genetic cause of perinatal thrombosis and cerebral palsy. *Developmental Medicine and Child Neurology*, **2007**, 41, 777-780	3.3	2
110	A novel defense against hemolytic-oxidative stress. *Blood*, **2006**, 108, 2504-2505	2.2	2
109	Low-dose methotrexate therapy for hepatoblastoma. *Cancer Chemotherapy and Pharmacology*, **1991**, 28, 233-4	3.5	2
108	Diastolic Dysfunction Is an Independent Risk Factor for Death in Patients with Sickle Cell Disease.. *Blood*, **2005**, 106, 206-206	2.2	2
107	The Anti-Sickling Agent Aes-103 Decreases Sickle Erythrocyte Fragility, Hypoxia-Induced Sickling and Hemolysis In Vitro. *Blood*, **2013**, 122, 940-940	2.2	2
106	Quantification of Anti-Sickling Effect of Aes-103 in Sickle Cell Disease Using an in Vitro Microfluidic Assay. *Blood*, **2014**, 124, 2699-2699	2.2	2
105	Neutrophil-Platelet Aggregation Enables Vaso-Occlusion in Sickle Cell Disease. *Blood*, **2016**, 128, 1295-1295	2.2	2
104	The Impact of Cognitive Function on Adherence to Hydroxyurea Therapy in Patients with Sickle Cell Disease. *Blood*, **2016**, 128, 2493-2493	2.2	2
103	Comment on "The influence of hydroxyurea on oxidative stress in sickle cell anemia". *Revista Brasileira De Hematologia E Hemoterapia*, **2012**, 34, 405-6		2
102	Identifying adolescent and young adult patients with sickle cell disease at highest risk of death. *American Journal of Hematology*, **2021**, 96, 9-11	7.1	2
101	The Role of Platelets in Sickle Cell Disease **2019**, 563-580		1
100	Reply: Practice guideline for pulmonary hypertension in sickle cell: direct evidence needed before universal adoption. *American Journal of Respiratory and Critical Care Medicine*, **2014**, 190, 238-40	10.2	1
99	**2012**,		1
98	Images in clinical medicine. Tumor pseudosyncytiae. *New England Journal of Medicine*, **2003**, 348, 1348	59.2	1
97	Arginine Metabolism, Pulmonary Hypertension, and Sickle Cell DiseaseReply. *JAMA - Journal of the American Medical Association*, **2005**, 294, 2432	27.4	1
96	A Phase II Trial of Topical Sodium Nitrite in Patients with Sickle Cell Disease and Leg Ulcers. *Blood*, **2019**, 134, 2292-2292	2.2	1
95	Oral Arginine Increases Erythrocyte Glutathione Levels in Sickle Cell Disease: Implications for Pulmonary Hypertension.. *Blood*, **2006**, 108, 1208-1208	2.2	1
94	Genetic Polymorphisms in NEDD4L Are Associated with Pulmonary Hypertension of Sickle Cell Anemia.. *Blood*, **2009**, 114, 2562-2562	2.2	1

93	Cytochrome b5 Reductase T116S Mutation and Hemolysis in Sickle Cell Disease.. *Blood*, **2009**, 114, 903-903	2.2	1
92	Plasma Level of NT-Pro-BNP In Children with Sickle Cell Disease Is Associated with Degree of Anemia and Left Ventricular Measures: The PUSH Study. *Blood*, **2010**, 116, 948-948	2.2	1
91	Clinical and Genetic Variability of Red Blood Cell Hemolysis in Sickle Cell Anemia. *Blood*, **2011**, 118, 1077-1077	2.2	1
90	Health Care Utilization for Painful Events Is Associated with Early Mortality in a Contemporary Population of Adults with Sickle Cell Anemia. *Blood*, **2011**, 118, 2115-2115	2.2	1
89	Predictors of Mortality in Children and Adolescents with Sickle Cell Disease: The PUSH Study. *Blood*, **2011**, 118, 515-515	2.2	1
88	Imaging Flow Cytometry for Fully Automated Quantification of Percentage of Sickled Cells in Sickle Cell Anemia.. *Blood*, **2012**, 120, 2105-2105	2.2	1
87	Effect of Aes-103 Anti-Sickling Agent On Oxygen Affinity and Stability of Red Blood Cells From Patients with Sickle Cell Anemia. *Blood*, **2012**, 120, 85-85	2.2	1
86	Stimulation of Nitric Oxide Synthase Activity By Plasma Apolipoproteins: a Biomarker of Endothelial Function in Adults with Sickle Cell Disease. *Blood*, **2014**, 124, 4015-4015	2.2	1
85	Prospective Evaluation of the Prevalence of Elevated Tricuspid Regurgitant Jet Velocity and Associated Clinical and Echocardiographic Factors in Children and Adolescents with Sickle Cell Disease.. *Blood*, **2007**, 110, 3388-3388	2.2	1
84	Hairy Platelet-Derived Extracellular Vesicles Promote Lung Vaso-Occlusion in Sickle Cell Disease. *Blood*, **2017**, 130, 958-958	2.2	1
83	A Cross-sectional Feasibility Study Testing the Use of Abstract Animations for the Communication and Assessment of Pain (Preprint)		1
82	Iron, Expression of the Pattern Recognition Receptor-Inflammasome System, and Early Death in Adults with Sickle Cell Disease. *Blood*, **2014**, 124, 2702-2702	2.2	1
81	Higher Myocardial and Skeletal Muscle Microvascular Flow in Sickle Cell Disease Patients on Hydroxyurea. *Blood*, **2016**, 128, 1020-1020	2.2	1
80	Sickle Cell Leg Ulcers Are Associated with Hyperuricemia, Hemolysis, Pulmonary Hypertension and Death.. *Blood*, **2009**, 114, 2583-2583	2.2	1
79	Non-Cardiopulmonary Factors Affecting the Six-Minute Walk Distance in Patients with Sickle Cell Disease: Results From the Walk-PHaSST Study. *Blood*, **2011**, 118, 1074-1074	2.2	1
78	Blood Flow Is Increased in Wounds and Peri-Wound Area by Laser Speckle Contrast Imaging and Infrared Thermography in Adults with Sickle Cell Leg Ulcers. *Blood*, **2012**, 120, 1009-1009	2.2	1
77	Gene therapy as the new frontier for Sickle Cell Disease. *Current Medicinal Chemistry*, **2021**,	4.3	1
76	Exercise training: a prescription for sickle-cell disease?. *Lancet Haematology,the*, **2018**, 5, e502-e503	14.6	1

75	Health-related quality of life in sickle cell disease. *Nature Reviews Disease Primers*, **2019**, 5, 27	51.1	0
74	Sickle particulars of microparticles. *Blood*, **2020**, 136, 154-155	2.2	0
73	Anemia, age, desaturation, and impaired neurocognition in sickle cell anemia. *Pediatric Blood and Cancer*, **2012**, 59, 773-4	3	0
72	Exercise-induced changes of vital signs in adults with sickle cell disease. *American Journal of Hematology*, **2021**, 96, 1630-1638	7.1	0
71	Impaired Bile Secretion Promotes Chronic Liver Injury in Sickle Cell Disease. *Blood*, **2019**, 134, 3536-3536	2.2	0
70	Imaging Flow Cytometry and Microfluidic Flow Assays Demonstrate Heterocellular Aggregation Of Immature Sickle Erythrocytes To Neutrophils Via Mac-1/VLA-4 Interactions. *Blood*, **2013**, 122, 318-318	2.2	0
69	Serum albumin is independently associated with higher mortality in adult sickle cell patients: Results of three independent cohorts. *PLoS ONE*, **2020**, 15, e0237543	3.7	0
68	147 A Prospective Phase II, Open-Label, Single-arm, Multicenter Study to Assess the Efficacy and Safety of SEG101 (Crizanlizumab) in Sickle Cell Disease Patients With Priapism (SPARTAN). *Journal of Sexual Medicine*, **2020**, 17, S43	1.1	
67	The Defective Arginine-Nitric Oxide Pathway in Sickle Cell Disease **2017**, 355-371		
66	Exercise Induced Changes of Vital Signs in Adults with Sickle Cell Disease. *Blood*, **2020**, 136, 59-60	2.2	
65	Microvascular Stasis Inhibition By Hemopexin in the Townes Mouse Model of Sickle Cell Disease. *Blood*, **2020**, 136, 9-9	2.2	
64	Prevention of Heme-Induced Human Endothelial Cell Activation By Hemopexin in Vitro. *Blood*, **2020** , 136, 8-8	2.2	
63	Targeted Proteomics of Pulmonary Hypertension in Sickle Cell Disease. *Blood*, **2021**, 138, 981-981	2.2	
62	Proteomic Identification of Dysregulated Apolipoprotein Expression in Pulmonary Hypertension Secondary to Sickle Cell Disease.. *Blood*, **2005**, 106, 3168-3168	2.2	
61	Mutations and Polymorphisms Influencing Hemolysis in Hemoglobin Genes and Risk of Pulmonary Hypertension in Sickle Cell Disease: Effect of Hemoglobin SC.. *Blood*, **2006**, 108, 1206-1206	2.2	
60	Arginine Metabolite Profiling in Sickle Cell Disease: Abnormal Levels and Correlations with Pulmonary Hypertension, Desaturation, Hemolysis and Organ Dysfunction.. *Blood*, **2006**, 108, 1205-1205	2.2	
59	Amplified Expression Profiling of Platelet Transcriptome Reveals Global Activation of Arginine Metabolic Pathways in Patients with Sickle Cell Disease.. *Blood*, **2006**, 108, 1536-1536	2.2	
58	Detection of the mRNA Transcription Level of Several Genes of the HIF and NO Metabolic Pathways in PBMCs of Sickle Cell Disease Patients Using Quantitative RT-PCR Assay.. *Blood*, **2007**, 110, 844-844	2.2	

57	Phosphodiesterase Inhibition Increases Fetal Hemoglobin in Sickle Cell Disease; L-Arginine Supplementation Does Not.. *Blood*, **2007**, 110, 3396-3396	2.2
56	Clinical and Laboratory Predictors of 30-Day Hospital Readmission Risk in Adult Patients with Sickle Cell Disease. *Blood*, **2018**, 132, 2384-2384	2.2
55	Assessment of Iron Overload Impact on QTc Interval in Patients with Sickle Cell Disease. *Blood*, **2018**, 132, 3673-3673	2.2
54	Heterogeneity in Multi-Organ Expression of HO-1 and PlGF in Sickle Mice Mimic Exposure of Non-Sickle Mice to Extracellular Heme Via Nrf2-Dependent Pathways. *Blood*, **2018**, 132, 2392-2392	2.2
53	A Prospective Phase II, Open-Label, Single-Arm, Multicenter Study to Assess the Efficacy and Safety of SEG101 (Crizanlizumab) in Sickle Cell Disease Patients with Priapism (SPARTAN). *Blood*, **2019**, 134, 1007-1007	2.2
52	360o View of a Day Hospital Program Performing Exchange Transfusion and Outpatient Pain Management on Adults with Sickle Cell Disease. *Blood*, **2019**, 134, 5873-5873	2.2
51	Sickle Cell Disease Promotes Dysregulation of Hepatic Iron Homeostasis By Regulating Hepcidin Expression. *Blood*, **2019**, 134, 958-958	2.2
50	Lactate Dehydrogenase to Carboxyhemoglobin Ratio As a Biomarker of Heme Release to Heme Processing Is Associated with Higher Tricuspid Regurgitant Jet Velocity and Early Death in Sickle Cell Disease. *Blood*, **2019**, 134, 2274-2274	2.2
49	Macrophage Hypercellularity Accompanies Erythroid Hyperplasia in Sickle Cell Mice and during Recovery from Blood Loss in Wild Type Mice. *Blood*, **2019**, 134, 3528-3528	2.2
48	Nrf2 Null Mice Are Deficient in CD169+ Macrophages, Associated with Impaired Erythroid Response and Delayed Recovery from Acute Blood Loss. *Blood*, **2019**, 134, 1038-1038	2.2
47	End-Alveolar Carbon Monoxide As a Measure of Erythrocyte Survival and Hemolytic Severity in Sickle Cell Disease. *Blood*, **2014**, 124, 2696-2696	2.2
46	Cardiopulmonary Functional Status in Children with SCD at Baseline: Pulse Pressure As a Biomarker of Early Compromise. *Blood*, **2014**, 124, 2663-2663	2.2
45	Elevated Pulse Pressure Is Associated with Hemolysis, Proteinuria and Chronic Kidney Disease in Sickle Cell Disease. *Blood*, **2014**, 124, 2711-2711	2.2
44	Association of FOXO3A Polymorphisms with Hematocrit, LDH and Longevity in Patients with Sickle Cell Anemia from CSSCD, Walk-Phasst, and PUSH Clinical Trials. *Blood*, **2015**, 126, 2176-2176	2.2
43	Thrombospondin-1 Gene Polymorphism Is Associated with Estimated Pulmonary Artery Pressure in Patients with Sickle Cell Anemia. *Blood*, **2015**, 126, 970-970	2.2
42	Platelet Nucleation on Arrested Neutrophils Drives Vaso-Occlusion in Sickle Cell Disease. *Blood*, **2015**, 126, 414-414	2.2
41	Heme Augments Toll-like Receptor 4 Signalling in Sickle Cell and Healthy Control Monocytes. *Blood*, **2015**, 126, 2167-2167	2.2
40	The Oxidant Response Transcription Factor NRF2 Mediates Heme Activation of Placenta Growth Factor Expression in Erythroid Cells, a Contributor to Pulmonary Hypertension in Sickle Cell Disease. *Blood*, **2015**, 126, 403-403	2.2

39	Structural and Functional Insight of Sphingosine 1-Phosphate-Mediated Pathogenic Metabolic Reprogramming in Sickle Cell Disease. *Blood*, **2016**, 128, 2474-2474	2.2
38	Hospitalization for Acute Pain in Sickle Cell Disease: Changes in Clinical Parameters and Factors Predicting Hospital Discharge and Re-Admission. *Blood*, **2016**, 128, 3662-3662	2.2
37	Amerindian/Asian Ancestry and Mortality Are Associated with Allo-Immunization in Adults with Sickle Cell Disease in a Genome Wide Racial Admixture Study. *Blood*, **2016**, 128, 3650-3650	2.2
36	Thrombospondin-1 Polymorphisms Are Associated with Chronic Kidney Disease in Sickle Cell Anemia. *Blood*, **2016**, 128, 2491-2491	2.2
35	Association of Hemolysis with Clinical Manifestations of Sickle Cell Disease. *Blood*, **2008**, 112, 2482-2482	2.2
34	Lower Ferritin Concentrations in Children with Sickle Cell Disease Are Associated with Decreased Hemolysis and Lower Tricuspid Regurgitant Velocity. *Blood*, **2008**, 112, 4810-4810	2.2
33	Oxygen Desaturation at Rest and after Exercise in Pediatric Sickle Cell Disease Patients: Correlations with Hemolysis and Elevated Tricuspid Regurgitant Jet Velocity.. *Blood*, **2008**, 112, 1423-1423	2.2
32	Placental Growth Factor Is Elevated in Patients with Sickle Cell Disease and Associated with Pulmonary Hypertension, Hemolysis, Inflammation, Iron Overload, and Hepatic Dysfunction.. *Blood*, **2009**, 114, 1531-1531	2.2
31	Lower Ferritin Concentrations Are Associated with Decreased Hemolysis in Sickle Cell Disease Children without Iron Overload.. *Blood*, **2009**, 114, 2571-2571	2.2
30	Hemolysis-Associated Elevation in Tricuspid Regurgitation Velocity Predicts Reduction in Six-Minute Walk Distance After Two Years of Follow up in Children and Adolescents with Sickle Cell Disease.. *Blood*, **2009**, 114, 574-574	2.2
29	Association of G6PD 202/376 with Lower Hemoglobin Concentration but Not Increased Hemolysis in Patients with Sickle Cell Anemia.. *Blood*, **2009**, 114, 1511-1511	2.2
28	Plasma Thrombospondin 1 Is Increased and Associated with Markers of Vasculopathy In Sickle Cell Disease. *Blood*, **2010**, 116, 946-946	2.2
27	NT-Probnp as a Marker of Cardiopulmonary Compromise and Exercise Limitation In Adults with Sickle Cell Anemia In the Walk-PHaSST Study. *Blood*, **2010**, 116, 1639-1639	2.2
26	Predictors of Six-Minute Walk Distance In Adults with Sickle Cell Anemia In the Walk-PHaSST Study. *Blood*, **2010**, 116, 947-947	2.2
25	Chronic Pain Is An Independent Predictor of Lower 6 Minute Walk Distance In Patients with Sickle Cell Disease: Results From Walk-PHaSST Study. *Blood*, **2010**, 116, 2658-2658	2.2
24	Evaluation of Exercise Capacity In Children with SCD by Six Minute Walk Test. *Blood*, **2010**, 116, 2664-2664	2.2
23	Serum B12 Levels In Children with Sickle Cell Disease Are Lower Than In Healthy Control Subjects. *Blood*, **2010**, 116, 1647-1647	2.2
22	Serum Transferrin: An Independent Predictor of Mortality in Sickle Cell Anemia. *Blood*, **2011**, 118, 2126-2126	2.2

21	A Cell-Based Adhesion Molecule Bioassay Detects Unexpected Properties of Plasma From Patients with Sickle Cell Disease with Documented Pulmonary Hypertension. *Blood*, **2011**, 118, 2120-2120	2.2
20	Iron Containing Compound Stimulates Expression of Pulmonary Hypertension Promoting Factor PlGF. *Blood*, **2011**, 118, 900-900	2.2
19	Integration of Genomic and Genetic Approaches Highlight a Novel Validated Gene Signature for Pulmonary Hypertension Associated with Sickle Cell Disease. *Blood*, **2011**, 118, 511-511	2.2
18	Increased Transpulmonary Gradient Predicts Functional Class, Mortality, and RV Dysfunction by MRI in Patients with Sickle Cell Associated Pulmonary Hypertension. *Blood*, **2012**, 120, 89-89	2.2
17	Turnover of Heme-Bound Iron Is Associated with Activation of TLR4 and Chemokine Receptor Pathways in the Peripheral Blood Mononuclear Cell Transcriptome in Sickle Cell Anemia. *Blood*, **2012**, 120, 819-819	2.2
16	Laser Speckle Contrast Imaging Characterizes Delayed Reperfusion After Transient Brachial Artery Occlusion in Patients with Sickle Cell Diseas. *Blood*, **2012**, 120, 1080-1080	2.2
15	A Phase 1, Dose-Escalation Study of Topical Sodium Nitrite in Patients with Sickle Cell Anemia and Leg Ulcers. *Blood*, **2012**, 120, 86-86	2.2
14	Genetic Determinants of Hemolysis in Sickle Cell Anemia.. *Blood*, **2012**, 120, 2104-2104	2.2
13	Topical Sodium Nitrite Is Effective In Reducing Leg Ulcer-Associated Pain In Patients With Sickle Cell Disease. *Blood*, **2013**, 122, 2236-2236	2.2
12	Placenta Growth Factor Is Regulated By Heme-Bound Iron Via Erythroid Krüppel-Like Factor In Erythroid Cells and Is Linked To Iron Status In Vivo In Sickle Cell Disease and Hereditary Hemochromatosis. *Blood*, **2013**, 122, 432-432	2.2
11	Imaging Flow Cytometry Documents Incomplete Resistance Of F-Cells To Hypoxia-Induced Sickling In Blood Samples From Patients With Sickle Cell Anemia. *Blood*, **2013**, 122, 183-183	2.2
10	Kynurenine-derived Electrophiles: Potential Adaptive Mediators in Sickle Cell Disease. *Free Radical Biology and Medicine*, **2020**, 159, S35-S36	7.8
9	Lactate dehydrogenase to carboxyhemoglobin ratio as a biomarker of heme release to heme processing is associated with higher tricuspid regurgitant jet velocity and early death in sickle cell disease. *American Journal of Hematology*, **2021**, 96, E315-E318	7.1
8	Sickle related events following cardiac catheterisation: risk implication for other invasive procedures. *British Journal of Haematology*, **2019**, 185, 778-780	4.5
7	Safety of liver biopsy in patients with sickle cell related liver disease - a single center experience.. *American Journal of Hematology*, **2022**,	7.1
6	Serum albumin is independently associated with higher mortality in adult sickle cell patients: Results of three independent cohorts **2020**, 15, e0237543	
5	Serum albumin is independently associated with higher mortality in adult sickle cell patients: Results of three independent cohorts **2020**, 15, e0237543	
4	Serum albumin is independently associated with higher mortality in adult sickle cell patients: Results of three independent cohorts **2020**, 15, e0237543	

List of Publications

3 Serum albumin is independently associated with higher mortality in adult sickle cell patients: Results of three independent cohorts **2020**, 15, e0237543

2 Serum albumin is independently associated with higher mortality in adult sickle cell patients: Results of three independent cohorts **2020**, 15, e0237543

1 Serum albumin is independently associated with higher mortality in adult sickle cell patients: Results of three independent cohorts **2020**, 15, e0237543